Skip to content
Research Article Open access CC BY 4.0

Effect of Co-administration of Vitamin A and Artesunate in Malaria-Infected Albino Mice

Onyemeh L. O., Freitas A. A., Olaide Z., Okoye A. C., Faloye D. A., Muoneke J. N.

Asian Journal of Research in Medical and Pharmaceutical Sciences · pp. 73–81 · Published 29 Jul 2023

10.9734/ajrimps/2023/v12i3223

Abstract

Malaria is a potentially fatal illness that results from infection by parasitic protozoa, which spread to humans via the bites of mosquitoes that have already been infected with the parasite. This research examines the impact of the simultaneous administration of Vitamin A and Artesunate on Plasmodium berghei-infected albino mice. A cohort of sixteen (16) albino mice, with a mean weight of 28g and indeterminate gender, were subjected to P. berghei inoculation. The mice were separated into four groups, each consisting of four animals. Artesunate was administered to Group A, distilled water was administered to Group B, Group C received antioxidant treatment in the form of vitamin A, and Group D was subjected to a combination treatment of Artesunate and Vitamin A. The study monitored the parasitemia level, hematocrit (PVC), percentage mortality rate, and change in body weight following the administration of various treatments, including an antimalarial drug (Artesunate), distilled water, Vitamin A, and a combination therapy of both Artesunate and Vitamin A. The co-administration of vitamin A and Artesunate may decrease the effectiveness of Artesunate in treating malaria infection. The research illustrates the intricate relationship between Artesunate and antioxidant (vitamin A) in mice infected with malaria. The efficacy of Artesunate in clearing the parasite was demonstrated by the reduction of Parasitaemia levels from +2(++) on the 5th day to +3 (+++) on the 7th day, followed by a decrease to +2(++) on the 9th day, and ultimately to +1(+) Parasitaemia on the 10th day. The co-administration of Vitamin A and Artesunate resulted in a reduction of the latter's efficacy in treating malaria, particularly in cases where the parasitemia level was at +3(+++) on the 5th, seventh, and 11th days and +2(++) on the ninth day. This procedure suggests that Vitamin A acted as an antagonist to the antimalarial effects of Artesunate. Furthermore, the mortality rate was 50%, and the PCV was reduced compared to Group A. Artesunate, a pro-oxidant that generates free oxygen radicals that act against the parasite. However, the presence of antioxidants like Vitamin A potentially counteracted the effects of pro-oxidants, indicating some form of pharmacological antagonism. The research findings indicate that the co-administration of vitamin A and Artesunate may reduce therapeutic effectiveness. Clinical interventions are recommended to be implemented to regulate the simultaneous administration of Artesunate and Vitamin A, as this may impact the therapeutic objective of malaria treatment.

Plasmodium berghei parasitaemia artesunate vitamin A mice

References (24)

  1. 1 Anaemia and malaria [DOI]
  2. 2 Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells [DOI]
  3. 3 Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins [DOI]
  4. 4 Reflections on the 2021 World Malaria Report and the future of malaria control [DOI]
  5. 5 Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate‑induced apoptosis [DOI]
  6. 6 Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials [DOI]
  7. 7 Vitamin A in health care: Suppression of growth and induction of differentiation in cancer cells by vitamin A and its derivatives and their mechanisms of action [DOI]
  8. 8 Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria [DOI]
  9. 9 Current Antimalarial Therapies and Advances in the Development of Semi-Synthetic Artemisinin Derivatives [DOI]
  10. 10 Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1α expression [DOI]
  11. 11 Dihydroartemisinin induces autophagy-dependent death in human tongue squamous cell carcinoma cells through DNA double-strand break-mediated oxidative stress [DOI]
  12. 12 Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL‐4—producing T cells and regulatory T cells [DOI]
  13. 13 Evaluation of Antimalarial Potential of Extracts from Alstonia boonei and Carica papaya in Plasmodium berghei-Infected Mice [DOI]
  14. 14 Antimalarial activity of the aqueous extract of the latex of Aloe pirottae Berger. (Aloaceae) against Plasmodium berghei in mice [DOI]
  15. 15 A newly synthesized oleanolic acid derivative inhibits the growth of osteosarcoma cells in vitro and in vivo by decreasing c‐MYC‐dependent glycolysis [DOI]
  16. 16 Preparation and characterization of a novel host-guest complex based on folate-modified β-cyclodextrin and artesunate [DOI]
  17. 17 Effects of lemon decoction on malaria parasite clearance and selected hematological parameters in Plasmodium berghei ANKA infected mice [DOI]
  18. 18 An analysis of the influence of sex hormones on Balb/c mice infected with Plasmodium berghei [DOI]
  19. 19 Ascorbic acid coadministration with artesunate–amodiaquine, up-regulated antioxidant enzymes gene expression in bone marrow cells and elicited biochemical changes in Plasmodium berghei-infected mice [DOI]
  20. 20 Modulation of anti-malaria immunity by vitamin A in C57BL/6J mice infected with heterogenic plasmodium [DOI]
  21. 21 Artesunate Attenuated the Progression of Abdominal Aortic Aneurysm in a Mouse Model [DOI]
  22. 22 Chromosomally integrated human herpes virus 6A ‐associated myocarditis in a neonate treated with artesunate [DOI]
  23. 23 Nonreductive homolytic scission of endoperoxide bond for activation of artemisinin: A parallel mechanism to Heterolytic cleavage [DOI]
  24. 24 Efficacy of Artesunate for Treatment of Cytomegalovirus Reactivations in Allogeneic Haematopoietic Stem Cell Transplant Recipients Who Are Intolerant/Unsuitable for Ganciclovir Therapy [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

13

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.